v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2025
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
General and administrative expenses $ 659 $ 82,675       $ 119,944        
Loss from operations (659) (82,675)       (119,944)        
Nonoperating Income (Expense) [Abstract]                    
Net Loss $ (659) $ (138,024,675) $ (37,269)     $ (138,061,944)        
Basic and diluted weighted average shares outstanding, redeemable ordinary shares (in shares) 100 100       100        
Basic and diluted net income per share, redeemable ordinary shares (in dollars per share) $ (6.59) $ (1,380,246.75)       $ (1,380,619.44)        
Diluted weighted average shares outstanding, non-redeemable ordinary shares (in shares) 100 100       100        
Diluted net income (loss) per share, non-redeemable ordinary shares (in dollars per share) $ (6.59) $ (1,380,246.75)       $ (1,380,619.44)        
Archimedes Tech SPAC Partners II Co [Member]                    
General and administrative expenses   $ 977,614   $ 150,006   $ 1,426,287 $ 307,457 $ 78,700 $ 785,975  
Loss from operations   (977,614)   (150,006)   (1,426,287) (307,457) (78,700) (785,975)  
Nonoperating Income (Expense) [Abstract]                    
Interest earned on cash in bank account           4,301,099 3,794,821   8,710,969  
PIPE subscription expense   (100,000,000)       (100,000,000) 0      
Unrealized Gain (Loss) on Derivatives   (37,942,000)       (37,942,000) 0      
Total other income (expense)   (135,775,308)   2,508,584   (133,621,832) 3,825,258 0 8,772,713  
Net Loss   $ (136,752,922) $ 1,704,803 $ 2,358,578 $ 1,159,223 $ (135,048,119) $ 3,517,801 $ (78,700) [1] $ 7,986,738  
Redeemable Ordinary Shares [Member] | Archimedes Tech SPAC Partners II Co [Member]                    
Nonoperating Income (Expense) [Abstract]                    
Basic and diluted weighted average shares outstanding, redeemable ordinary shares (in shares)   23,000,000   23,000,000   23,000,000 17,535,912 0 20,290,411  
Basic and diluted net income per share, redeemable ordinary shares (in dollars per share)   $ (4.62)   $ 0.08   $ (4.56) $ 0.15 $ 0 $ 0.3  
Diluted weighted average shares outstanding, non-redeemable ordinary shares (in shares)   23,000,000   23,000,000   23,000,000 17,535,912   20,290,411  
Diluted net income (loss) per share, non-redeemable ordinary shares (in dollars per share)   $ (4.62)   $ 0.08   $ (4.56) $ 0.15   $ 0.3  
Non-redeemable Ordinary Shares [Member] | Archimedes Tech SPAC Partners II Co [Member]                    
Nonoperating Income (Expense) [Abstract]                    
Basic and diluted weighted average shares outstanding, redeemable ordinary shares (in shares)   6,590,000   6,590,000   6,590,000 6,212,265 5,000,000 [2] 6,402,685 [2] 5,000,000
Basic and diluted net income per share, redeemable ordinary shares (in dollars per share)   $ (4.62)   $ 0.08   $ (4.56) $ 0.15 $ (0.02) $ 0.3 $ (0.02)
Diluted weighted average shares outstanding, non-redeemable ordinary shares (in shares)   6,590,000   6,590,000   6,590,000 6,386,298 5,000,000 [2] 6,488,986 [2] 5,000,000
Diluted net income (loss) per share, non-redeemable ordinary shares (in dollars per share)   $ (4.62)   $ 0.08   $ (4.56) $ 0.15 $ (0.02) $ 0.3 $ (0.02)
Cash In Bank Account [Member] | Archimedes Tech SPAC Partners II Co [Member]                    
Nonoperating Income (Expense) [Abstract]                    
Interest earned on cash in bank account   $ 7,555   $ 19,647   $ 19,069 $ 30,437 $ 0 $ 61,744  
Cash Held In Trust Account [Member] | Archimedes Tech SPAC Partners II Co [Member]                    
Nonoperating Income (Expense) [Abstract]                    
Interest earned on cash in bank account   $ 2,159,137   $ 2,488,937   $ 4,301,099 $ 3,794,821 $ 0 $ 8,710,969  
[1] As of December 31, 2024, included an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.
[2] Prior to the Company’s Initial Public Offering, the ordinary shares excluded an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.